YiSheng BioPharma Reports Early Success For Its Adjuvant In Ebola Vaccine

Jilin Jian Yisheng Biopharma and the US Army Medical Research Institute of Infectious Diseases reported positive animal results for an Ebola vaccine. The vaccine combines a virus-like particle-based vaccine developed by the USMRIID with Yisheng's PIKA adjuvant, a Toll-Like Receptor 3 agonist. By itself, the vaccine provided protection for 40% of the animals. With Yisheng's adjuvant, 100% of the animals survived an Ebola infection. Yisheng, which makes vaccines and pharma products, announced the collaboration with USAMRI in late 2015.